Provided by Tiger Fintech (Singapore) Pte. Ltd.

Ocular Therapeutix

9.02
+0.56006.62%
Post-market: 9.200.1800+2.00%19:39 EDT
Volume:2.15M
Turnover:19.09M
Market Cap:1.44B
PE:-7.84
High:9.04
Open:8.55
Low:8.50
Close:8.46
Loading ...

Chief Medical Officer Nadia Waheed Reports Disposal of Common Shares of Ocular Therapeutix Inc

Reuters
·
04 Jun

Ocular Therapeutix Price Target Maintained With a $15.00/Share by HC Wainwright & Co.

Dow Jones
·
30 May

Clear Street Reaffirms Their Buy Rating on Ocular Therapeutix (OCUL)

TIPRANKS
·
29 May

Ocular Shares Rise After Eye Disease Trial Nears Enrollment Completion

MT Newswires Live
·
29 May

Strong Buy Rating for Ocular Therapeutix Driven by Promising Axpaxli Program and Market Potential

TIPRANKS
·
28 May

Ocular Therapeutix to close enrollment this week for SOL-R

TIPRANKS
·
28 May

Ocular Therapeutix Chief Strategy Officer Sanjay Nayak Reports Disposal of Common Shares

Reuters
·
28 May

Pravin Dugel, Director and Officer of Ocular Therapeutix Inc., Reports Disposal of Common Shares

Reuters
·
28 May

Director Richard L. Lindstrom, MD Reports Acquisition of Common Shares in Ocular Therapeutix Inc

Reuters
·
13 May

Ocular Therapeutix (OCUL) Gets a Buy from Scotiabank

TIPRANKS
·
06 May

Ocular Therapeutix Is Maintained at Buy by Needham

Dow Jones
·
06 May

Ocular Therapeutix (OCUL) Stock Drops 13% After Q1 Earnings

Benzinga
·
06 May

Strategic Advancements and Financial Updates Drive Buy Rating for Ocular Therapeutix

TIPRANKS
·
06 May

Ocular Therapeutix Stock Falls as 1Q Misses Targets, R&D Expenses Double

Dow Jones
·
05 May

Ocular Therapeutix Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
05 May

Ocular Therapeutix Shares Drop 5.8% Premarket After Q1 Results

THOMSON REUTERS
·
05 May

Ocular Therapeutix Q1 Net Loss Narrows, Revenue Falls

MT Newswires Live
·
05 May

Ocular Therapeutix reports Q1 EPS (38c), consensus (28c)

TIPRANKS
·
05 May

Ocular Therapeutix sees cash runway into 2028

TIPRANKS
·
05 May

Earnings Flash (OCUL) Ocular Therapeutix Posts Q1 Net Loss $0.38 a Share, vs. FactSet Est of $0.29 Loss

MT Newswires Live
·
05 May